Intraoperative Radiotherapy (IORT) with Low-Energy Photons as a Boost in Patients with Early-Stage Oral Cancer with the Indications for Postoperative Radiotherapy

Abstract

This preliminary report has demonstrated the feasibility of IORT-PRS for patients with early oral cancer with the indications for postoperative radiotherapy. This method may be considered an alternative boost technique, although additional studies are needed to establish long-term results in a larger group of patients.

Cystatin C – A Fast and Reliable Biomarker for Glomerular Filtration Rate in Head and Neck Cancer Patients

“…Already partial renal insufficiency frequently poses an obstacle to therapeutic decisions and may lead to accumulation of chemotherapeutic agents and their metabolites. The nephrotoxicity of cisplatin is dose-related, cumulative, and depends on the extent of diuresis and the preexisting renal dysfunction [10,21,[23][24][25][26]33]. Therefore, an accurate estimation of renal function is needed for safe and effective use of this chemotherapeutic agent to prohibit toxic side effects [2,33].…”

Japanese Structure Survey of Radiation Oncology in 2007 with Special Reference to Designated Cancer Care Hospitals

“…In developed countries in Europe, such as France, Germany, Italy, and the UK, as well as in the United States, the rates of radiotherapy use for cancer treatment are as high as 50% or more because there are sufficient radiotherapy facilities and personnel, such as radiation oncologists (ROs), medical physicists (MPs), and radiotherapy technologists (RTTs) [1,2,5,11]. On the other hand, the current utilization rate of radiotherapy for new cancer patients in Japan is only 26.1% [19] and surgery is still predominant.…”

Combined-modality treatment in advanced oral squamous cell carcinoma

“…Approximately 80-90% of patients with stage I oral squamous cell carcinoma (OSCC) are cured with surgery or radiotherapy (RT) alone, outcome for patients with advanced stage tumors, however, remains poor, yielding 5-year survival rates from 45-53% [15,22,42]. Locoregional recurrences and distant metastases are frequent after surgical resection of advanced stage OSCC [7].…”